327 related articles for article (PubMed ID: 26787699)
1. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
Baranovich T; Jones JC; Russier M; Vogel P; Szretter KJ; Sloan SE; Seiler P; Trevejo JM; Webby RJ; Govorkova EA
Antimicrob Agents Chemother; 2016 Apr; 60(4):2118-31. PubMed ID: 26787699
[TBL] [Abstract][Full Text] [Related]
2. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
3. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
Farooqui A; Huang L; Wu S; Cai Y; Su M; Lin P; Chen W; Fang X; Zhang L; Liu Y; Zeng T; Paquette SG; Khan A; Kelvin AA; Kelvin DJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7255-64. PubMed ID: 26369969
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.
Winarski KL; Tang J; Klenow L; Lee J; Coyle EM; Manischewitz J; Turner HL; Takeda K; Ward AB; Golding H; Khurana S
Proc Natl Acad Sci U S A; 2019 Jul; 116(30):15194-15199. PubMed ID: 31296560
[TBL] [Abstract][Full Text] [Related]
6. Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication.
Shen W; Wang Q; Wang Z; Liu M; Du Y; Yuan L; Han L; Smietanka K; Chen H; Xu S; Zhu Q
J Virol; 2022 Sep; 96(18):e0123822. PubMed ID: 36037479
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
[TBL] [Abstract][Full Text] [Related]
8. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.
Yang P; Gu H; Zhao Z; Wang W; Cao B; Lai C; Yang X; Zhang L; Duan Y; Zhang S; Chen W; Zhen W; Cai M; Penninger JM; Jiang C; Wang X
Sci Rep; 2014 Nov; 4():7027. PubMed ID: 25391767
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
11. A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.
Yu F; Song H; Wu Y; Chang SY; Wang L; Li W; Hong B; Xia S; Wang C; Khurana S; Feng Y; Wang Y; Sun Z; He B; Hou D; Manischewitz J; King LR; Song Y; Min JY; Golding H; Ji X; Lu L; Jiang S; Dimitrov DS; Ying T
Cell Host Microbe; 2017 Oct; 22(4):471-483.e5. PubMed ID: 28966056
[TBL] [Abstract][Full Text] [Related]
12. Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus.
Wang C; Liu P; Luo J; Ding H; Gao Y; Sun L; Luo F; Liu X; He H
Front Cell Infect Microbiol; 2017; 7():267. PubMed ID: 28664154
[TBL] [Abstract][Full Text] [Related]
13. A broadly neutralizing human monoclonal antibody is effective against H7N9.
Tharakaraman K; Subramanian V; Viswanathan K; Sloan S; Yen HL; Barnard DL; Leung YH; Szretter KJ; Koch TJ; Delaney JC; Babcock GJ; Wogan GN; Sasisekharan R; Shriver Z
Proc Natl Acad Sci U S A; 2015 Sep; 112(35):10890-5. PubMed ID: 26283346
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.
Ito M; Yamayoshi S; Murakami K; Saito K; Motojima A; Nakaishi K; Kawaoka Y
Viruses; 2019 Feb; 11(2):. PubMed ID: 30754701
[TBL] [Abstract][Full Text] [Related]
15. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
[TBL] [Abstract][Full Text] [Related]
16. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
[TBL] [Abstract][Full Text] [Related]
17. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
Fukushi M; Yamashita M; Miyoshi-Akiyama T; Kubo S; Yamamoto K; Kudo K
PLoS One; 2012; 7(8):e42419. PubMed ID: 22879974
[TBL] [Abstract][Full Text] [Related]
18. In vivo anti-influenza virus activity of kampo (Japanese herbal) medicine "sho-seiryu-to" and its mode of action.
Nagai T; Yamada H
Int J Immunopharmacol; 1994 Aug; 16(8):605-13. PubMed ID: 7527377
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C.
Kim EH; Pascua PN; Song MS; Baek YH; Kwon HI; Park SJ; Lim GJ; Kim SM; Decano A; Lee KJ; Cho WK; Ma JY; Choi YK
Antiviral Res; 2013 Jun; 98(3):386-93. PubMed ID: 23588232
[TBL] [Abstract][Full Text] [Related]
20. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.
Shen C; Chen J; Li R; Zhang M; Wang G; Stegalkina S; Zhang L; Chen J; Cao J; Bi X; Anderson SF; Alefantis T; Zhang M; Cai X; Yang K; Zheng Q; Fang M; Yu H; Luo W; Zheng Z; Yuan Q; Zhang J; Wai-Kuo Shih J; Kleanthous H; Chen H; Chen Y; Xia N
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
